Navigation Links
EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
Date:6/16/2008

Therapy (CST(TM)) offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced bio-active therapeutic solutions to a controlled wound environment. DermaStream(TM) is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment cycle from debridement, through regeneration to wound closure. DermaStream(TM) was designed for use in hospitals, clinics, nursing homes and for home care.

EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients by shortening healing time, preventing hospitalization and reducing treatment costs. visit http://www.dermastream.com

PR Contacts:

Boaz Gruener, Director of Marketing and Business Development

boazg@dermastream.com

+972-54-4563608


'/>"/>
SOURCE EnzySurge Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
2. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
3. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
4. Ortho Evra Patch Makers Settling Cases
5. New research shows that iPods do not interfere with cardiac pacemakers
6. Bioscience Group Warns Policymakers Against Complacency
7. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
8. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
9. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. BioMarin to Present at the BioCentury NewsMakers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2